Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 17/20 | 0.84 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4886391 | 0.96 | DGAT1 (0.77) | DGAT1RAB9AKDM4EMEN1NPC1 | |
| SCHEMBL4894007 | 0.93 | DGAT1 (0.96) | DGAT1RAB9ALMNAKDM4EMEN1 | |
| SCHEMBL4890716 | 0.92 | DGAT1 (1.00) | DGAT1RAB9ALMNAKDM4EMEN1 | |
| SCHEMBL4898766 | 0.82 | DGAT1 (0.74) | DGAT1 | |
| SCHEMBL4883126 | 0.79 | DGAT1 (0.77) | DGAT1RAB9ALMNAMEN1NPC1 | |
| SCHEMBL4893436 | 0.79 | DGAT1 (0.95) | DGAT1RAB9ALMNA | |
| SCHEMBL5446047 | 0.79 | DGAT1 (0.95) | DGAT1RAB9ALMNA | |
| SCHEMBL4890050 | 0.79 | DGAT1 (0.58) | DGAT1RAB9AMEN1NPC1KMT2A | |
| SCHEMBL4890678 | 0.78 | DGAT1 (0.80) | DGAT1RAB9ALMNAKDM4EMEN1 | |
| SCHEMBL21995882 | 0.78 | DGAT1 (1.00) | DGAT1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015227-A1 | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme | ABBOTT LABORATORIES | 2008-01-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015227-A1 | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme | DGAT1, DGAT2, LCAT | DGAT1 1/4885RAB9A 1464/4885LMNA 3292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.